ARS Pharmaceuticals
SPRY
68 hedge funds and large institutions have $1.21B invested in ARS Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 23 closing their positions.
221% more capital inflows, than outflows
Capital inflows: $224M | Capital outflows: $69.9M
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
10% more funds holding
Funds holding: 62 → 68 (+6)
9.33% more ownership
Funds ownership: 70.26% → 79.6% (+9.3%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49M |
| 3 |
BlackRock
New York
|
+$39.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.6M |
| 5 |
D.E. Shaw & Co
New York
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.1M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$8.28M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.4M |
| 4 |
Millennium Management
New York
|
-$6.12M |
| 5 |
Goldman Sachs
New York
|
-$4.07M |
SPRY Hedge Fund Activity: Q1 2021 in Review
68 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2021, worth a combined $1.21B — up 6.9% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SPRY positions and 23 closed out — a net gain of 6 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $65.5M. The largest seller was Nantahala Capital Management, cutting an estimated $10.1M.
- 68 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2021, up from 62 in Q4 2020.
- Funds reported $1.21B of ARS Pharmaceuticals stock for Q1 2021, up 6.9% quarter-over-quarter.
- 29 funds opened new ARS Pharmaceuticals positions in Q1 2021 and 23 closed out, a net change of +6 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $65.5M added.
- The largest ARS Pharmaceuticals seller in Q1 2021 was Nantahala Capital Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2021.